HOME ·

02335.HK

MICOT PHARMA-B (02335.HK): Preclinical and Phase I data of neuroprotective candidate MT200605 accepted for oral presentation at 2026 World Stroke Congress; Phase II meets primary endpoint
Tags：
Micot Pharma-B02335.HKR&D Progress
2026-08-11
Shaanxi Micot Pharmaceutical Technology (02335.HK): Phase II Trial of MT200605 for Acute Ischemic Stroke Meets Primary Endpoint
Tags：
Shaanxi Micot Pharmaceutical Technology02335.HK
2026-08-04
Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment
Tags：
Micot Pharma02335.HKClinical Trial
2026-07-09
MICOT PHARMA-B(02335.HK) closed 102.75% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends
Tags：
Micot Pharma-B02335.HK
2026-06-24
Micot Pharma-B (02335.HK): Grey Market Surges 84.18% to HK$33.52
Tags：
Micot Pharma-B02335.HKGrey MarketIPO
2026-06-23
Micot Pharma-B (02335.HK) Launches IPO: Max Offer Price at HK$21.0, Entry Fee Around HK$4,242 per Lot
Tags：
Micot Pharma02335.HKIPO
2026-06-15